Coronavirus envelope protein is a drug target for new platform for the identification and optimization of peptides against SARS-CoV-2
#####
In your coverage, please use this URL to provide access to the freely available paper in PLOS Biology : http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3002522
Article Title: Developing inhibitory peptides against SARS-CoV-2 envelope protein
Author Countries : United States
Funding: This work was supported by Columbia University Dean’s Office Fund and Columbia University Translational Therapeutics (TRx) Pilot Award (to M.Y.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
PLOS Biology
Experimental study
Cells
Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: M.Y., R.B., K.Y., D.D.H., M.S.N., and Y.H. (inventors) filed a patent (Attorney Docket No.: 01001/00889-US0; status: Filed, 04/13/2022) related to this manuscript. This patent is for using synthetic peptides targeting SARS-CoV-2 envelope protein for treating COVID-19 and related human coronaviruses. The rest of the authors declare no competing interests.